Federated Investors Inc. PA lowered its stake in Entellus Medical, Inc. (NASDAQ:ENTL) by 57.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 93,500 shares of the medical technology company’s stock after selling 126,600 shares during the quarter. Federated Investors Inc. PA owned approximately 0.43% of Entellus Medical worth $1,548,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of ENTL. Frontier Capital Management Co. LLC bought a new position in Entellus Medical in the 1st quarter worth about $6,464,000. William Blair Investment Management LLC boosted its stake in Entellus Medical by 1,017.0% in the 1st quarter. William Blair Investment Management LLC now owns 390,334 shares of the medical technology company’s stock worth $5,387,000 after purchasing an additional 355,388 shares during the period. Kingdon Capital Management L.L.C. boosted its stake in Entellus Medical by 79.6% in the 1st quarter. Kingdon Capital Management L.L.C. now owns 450,371 shares of the medical technology company’s stock worth $6,215,000 after purchasing an additional 199,615 shares during the period. Grandeur Peak Global Advisors LLC boosted its stake in Entellus Medical by 868.1% in the 1st quarter. Grandeur Peak Global Advisors LLC now owns 212,491 shares of the medical technology company’s stock worth $2,932,000 after purchasing an additional 190,541 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Entellus Medical by 77.8% in the 1st quarter. Vanguard Group Inc. now owns 424,823 shares of the medical technology company’s stock worth $5,862,000 after purchasing an additional 185,833 shares during the period. Institutional investors and hedge funds own 70.41% of the company’s stock.

ENTL has been the subject of several analyst reports. ValuEngine downgraded Entellus Medical from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 23rd. Piper Jaffray Companies restated a “buy” rating and issued a $21.00 target price on shares of Entellus Medical in a research note on Tuesday, August 22nd. BidaskClub upgraded Entellus Medical from a “hold” rating to a “buy” rating in a research note on Saturday, August 19th. Zacks Investment Research downgraded Entellus Medical from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Finally, Canaccord Genuity set a $18.00 target price on Entellus Medical and gave the stock a “hold” rating in a research note on Monday, May 22nd. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. Entellus Medical has a consensus rating of “Hold” and a consensus target price of $21.71.

Shares of Entellus Medical, Inc. (NASDAQ:ENTL) opened at 17.13 on Wednesday. The company’s market cap is $434.61 million. The stock’s 50 day moving average price is $17.36 and its 200-day moving average price is $14.33. Entellus Medical, Inc. has a 12 month low of $12.31 and a 12 month high of $22.57.

Entellus Medical (NASDAQ:ENTL) last issued its quarterly earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). The company had revenue of $22.10 million during the quarter, compared to analysts’ expectations of $21.87 million. Entellus Medical had a negative return on equity of 60.34% and a negative net margin of 41.11%. The business’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.27) EPS. Equities research analysts expect that Entellus Medical, Inc. will post ($1.61) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Federated Investors Inc. PA Has $1.55 Million Holdings in Entellus Medical, Inc. (ENTL)” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/09/13/federated-investors-inc-pa-has-1-55-million-holdings-in-entellus-medical-inc-entl.html.

Entellus Medical Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Want to see what other hedge funds are holding ENTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Entellus Medical, Inc. (NASDAQ:ENTL).

Institutional Ownership by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.